[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616292":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":22,"responsibleParty":38,"collaborators":7,"id":40,"slug":7,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":7,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Palo Alto Veterans Institute for Research","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Sirish Kishore, MD","VA Palo Alto Health Care System","PRINCIPAL_INVESTIGATOR",[14,19],{"name":10,"role":15,"phone":16,"phoneExt":17,"email":18},"CONTACT","650-493-5000","61706","sirish.kishore@va.gov",{"name":20,"role":15,"phone":16,"phoneExt":17,"email":21},"Luisa Manfredi, MPH","luisa.manfredi1@va.gov",[23],{"facility":11,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"RECRUITING","Palo Alto","California","94304","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-122.14302,37.44188,{"lat":34,"lon":33},[37],{"name":10,"role":15,"phone":16,"phoneExt":17,"email":7},{"type":39,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100616292",false,"NCT07303712","Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90","Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization and Assessment of Treatment Response After Y90 Radioembolization: A Pilot Study","Inclusion Criteria:\n\n1. Age \\> or = 18 years\n2. HCC confirmed on imaging, BCLC stage 0, A, B, or C\n3. Transarterial Y90 radioembolization approved by multidisciplinary tumor board -\n\nExclusion Criteria:\n\n1. Not eligible for Y90 procedure\n2. Prior surgery or ablation on indicated tumors\n3. Patient unable to complete the follow up visits required for clinical care or research -","ALL","18 Years",{"count":49,"type":50},12,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).",[54],"Hepatocellular Carcinoma (HCC)",[56,57],"Circulating tumor cell (CTC)","y90","2025-12-18",{"date":60,"type":61},"2025-12-26","ACTUAL",{"date":63,"type":61},"2024-08-01",{"date":65,"type":50},"2026-12-01",{"name":5,"class":6},1]